Dialysis industry news

Stories from the dialysis comunity across the globe.

Most Pediatric Pyeloplasty Patients Have Imaging Within a Year - Renal and Urology News PDF Print
August 21, 2015 Within first 12 months, 91% undergo at least 1 imaging study, most often ultrasound.
Within first 12 months, 91% undergo at least 1 imaging study, most often ultrasound.

(HealthDay News) -- Most patients are followed up after pediatric pyeloplasty, with ultrasound being the most common imaging modality, according to a study published in The Journal of Urology.

Ryan S. Hsi, M.D., from Seattle Children's Hospital, and colleagues characterized trends in frequency and modality of postoperative imaging after open and minimally invasive pediatric pyeloplasty. Pediatric patients (aged 0 to 18 years) undergoing pyeloplasty between 2007 and 2013 were identified using the MarketScan database. Follow-up imaging was classified as functional or nonfunctional.

The researchers identified 926 patients, of whom 30% underwent minimally invasive pyeloplasty. No postoperative imaging was available for 5.9% of patients. Most patients (91%) underwent at least 1 imaging study within the first 6 months postoperatively, and 24% underwent renography (functional imaging). The same number (91%) underwent at least 1 imaging study within the first 12 months postoperatively, most commonly ultrasound. Almost one-third of patients were not followed with imaging after 12 months. Most of the 71% undergoing imaging underwent ultrasound. On multivariate analysis, younger age and female gender were independently associated with frequent imaging.

"Following pediatric pyeloplasty there is variation in modality and frequency of imaging follow-up," the authors write. "The majority of patients are followed with renal ultrasound, with less frequent use of functional imaging."

One author disclosed financial ties to C-SATS Inc.


  1. Hsi, RS; Holt, SK; Gore, JL; Lendvay, TS; Harper, JD. The Journal of Urology; doi: 10.1016/j.juro.2015.03.123.


Home dialysis patients getting break on utility bills - Brandon Sun PDF Print

WINNIPEG — Manitoba will become the first province to pay the added water and electricity costs for dialysis patients who are approved for treatment at home.

Health Minister Sharon Blady says the goal for home hemodialysis patients is not only to lessen the stress of treatment, but to reduce the cost of hospital or clinical treatment.

The number of dialysis patients is increasing with more diabetes patients and an aging population. As a result, Manitoba has among the highest incidence of new patients and prevalence (total patients) of dialysis use in Canada. It’s estimated that each year 80 new patients need dialysis, meaning 14 more clinical spots have to open for treatment — a rate that’s taxing the health-care system.

“We’ve got these challenges where we’ve got increasing numbers,” Blady said Thursday. ‘Once people get trained for it, and know how to do it at home, they find it really empowering.

“To me it does wonderful things,” she added. “We’re able to give a better quality of care at home, which gives a better quality of life, and it saves money that can be reinvested for caring more folks.”

The additional hydro and water costs for home treatment range from about $700 to $2,000 a year in Winnipeg, she added.

The reimbursement program will be administered by the Manitoba Branch of the Kidney Foundation of Canada. More details about the provincial reimbursement program will be available for those who are eligible in early October. It will be backdated to last April.

Blady said the operating cost for home dialysis is about 50 per cent less than what it would be in a hospital. Home treatment reduces exposure to hospital bugs and infections.

Mukhtiar Singh said when he began nocturnal home hemodialysis in 2009 — he’s been on dialysis for 20 years—he saw his utility bills jump by $1,800 a year.

Singh, 67, is member of a patient advocacy group that pushed for the reimbursement program. His treatment takes about eight hours five nights a week, with his home water-treatment system being the largest expense.

He said if the province can get 300 people on home hemodialysis, the health-care system could save $40,000 to $50,000 a year per patient.

“We’d be looking at $12 million to $15 million per year saving to Manitoba Health,” he said. “It saves money. It takes pressure off the system, and the patient’s quality of life gets better.”

Dr. Mauro Verrelli of the St. Boniface General Hospital, medical director for Manitoba Renal Program, said many patients with less complex treatments can be treated at home.

“I think the strength of this program is that people who may have not wanted to do home hemodialysis because they were worried about paying up to $2,000 a year in utility bills now can say they don’t have that problem,” Verrelli said.

He said a reasonable target is to have 30 per cent of hemodialysis (artificial kidney machine) and peritoneal dialysis (blood is cleaned inside the body, using it as a natural filter, rather than being cleaned outside in a machine) patients treated at home.

He said right now four per cent of hemodialysis patients are treated at home. About 20 per cent of peritoneal dialysis patients are treated at home.

“If we went to 30 per cent over the next few years, that would be great,” he said. “Unfortunately, there is a net yearly growth that is taxing the health system, and that everybody is striving to do their due diligence to contain, but diabetes rates are increasing, chronic disease rates are increasing and people are aging. More people need dialysis.”

» Winnipeg Free Press

Republished from the Brandon Sun print edition August 21, 2015


Dialysis centre for Northern Division - Fiji Times PDF Print

/ Front page / News

Friday, August 21, 2015

Update: 6:20PM KIDNEY patients in the north are expected to benefit from the newly-opened Northern Dialysis Centre.

Speaking during the opening of the centre, Hazeem Hussein revealed that people in the North could now access dialysis treatment for a fee of $150 at the $250,000 worth new centre.

"In Suva, the cost of such treatment is worth $250 while it costs around $300 to access such treatments in the West," he said.

Also present at the official opening today was the Minister for Health and Medical Services, Jone Usamate.

The new centre is a brainchild of Mr Hussein.


Rockwell Medical, Inc. Price Target Update - Money Flow Index PDF Print

Rockwell Medical, Inc. (NASDAQ:RMTI) stock has received a short term price target of $ 15 from 6 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $8.15. The higher estimate of target price is $26 , while the lower price target estimate is $4

Rockwell Medical, Inc. (NASDAQ:RMTI) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 2.55 by 6 Wall Street Analysts. 3 analysts have added the shares in their list of strong buys. 1 analysts have advised hold. 2 has rated the company as strong sell. Several analysts have commented on the company rating. In a research note released to the investors, Morgan Stanley initiates coverage on its rating on Rockwell Medical, Inc. (NASDAQ:RMTI).The analysts at the brokerage house have a current rating of Underweight on the shares. In a recent information released to the investors, Morgan Stanley announces the price target of $7 per share. The rating by the firm was issued on August 13, 2015. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Thursday session in red amid volatile trading. The shares closed down 0.64 points or 5.47% at $11.05 with 1,082,747 shares getting traded. Post opening the session at $11.51, the shares hit an intraday low of $10.961 and an intraday high of $11.99 and the price vacillated in this range throughout the day. The company has a market cap of $555 million and the number of outstanding shares have been calculated to be 50,223,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is $18.8999 and the 52-week low is $8.095. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at $11.96 per share with total amount equaling $58,724. Rockwell Medical, Inc. has lost 4.25% in the last five trading days and dropped 33.95% in the last 4 weeks. Rockwell Medical, Inc. is up 7.18% in the last 3-month period. Year-to-Date the stock performance stands at 7.49%. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.


Dialysis catheters market in US 2015 to grow at a CAGR of 2.11% by 2019. - Medgadget.com (blog) PDF Print

About dialysis catheter:-

Dialysis catheter is a device required to provide vascular access to dialysis equipment for carrying out dialysis. It is inserted into a vein in the groin (under the collarbone, or in the neck). This catheter has two separate tubes, one of which carries blood from a patient to the dialysis machine, and the other helps return blood to the body. This device can be used for both long-term and short-term access; however, it is not recommended for long-term access.

Dialysis catheters market in the US to grow at a CAGR of 2.11% over the period 2015-2019.

Covered in this report:-

The Dialysis catheters market in the US is segmented into two based on product type: acute dialysis catheters and chronic dialysis catheters.

Dialysis Catheters Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the dialysis catheters market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Request For Sample @ http://www.marketresearchstore.com/report/dialysis-catheters-market-in-the-us-2015-2019-13095#requestSample

Key vendors

C.R. Bard
Medical Components
Other prominent vendors
Argon Medical Devices
Baxter International
Merit Medical Systems

Visit Complete Table of Content Here:

Market driver

Growing ESRD and CKD patient population
For a full, detailed list, view our report

Market challenge

Presence of alternative devices
For a full, detailed list, view our report

Market trend

Increase in use of minimally invasive techniques
For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?


<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 4210
Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.